Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft terms for the Institute’s calculators — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-029/3
Series
Public comment period
Version
1.0
Published
01 May 2025
Last reviewed
01 May 2025
Next review
01 May 2026
Identifier
10.71829/cei.cp.29
Certainty
Not rated
Cycle
2025 Q1
Window
07 Feb 2025 – 24 Mar 2025
Status
Closed
Submissions
18

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-TOOLS-DISCLA/015Dr Rukayat Zaleski-MbekiThe Institute publishes no telephone number and no messaging channelNoted, no amendment
DRAFT-TOOLS-DISCLA/016Rosalind PetrossianAn industry submission should be identifiable without reading the declared interestAccepted
DRAFT-TOOLS-DISCLA/009Dr Fenella Steenkamp-FerreiraThe same concept is given three different names in one documentAccepted
DRAFT-TOOLS-DISCLA/013Dr Ngozi ZetterlundThe position of a contributor who withdraws consent is not statedAccepted
DRAFT-TOOLS-DISCLA/014Kolawole Jankowiak-OseiWhether external reviewers are paid is not statedAccepted
DRAFT-TOOLS-DISCLA/010Ms Rhiannon Okoye-VandergraafA sortable table implies a comparison the underlying data do not supportNoted, no amendment
DRAFT-TOOLS-DISCLA/008Dr Stellan Cholmondeley-AdeThe document should state what a reader ought to doNot accepted
DRAFT-TOOLS-DISCLA/001Dr Rurik Underhill-OkaforA party criticised in an assessment should have a right of replyAccepted in part
DRAFT-TOOLS-DISCLA/007Xiomara Fairweather-DuruThe terms on which the documents may be reused are not statedAccepted
DRAFT-TOOLS-DISCLA/002Xenia Nyquist-ObioraThe secretariat answers submissions and is not itself namedAccepted in part
DRAFT-TOOLS-DISCLA/012Dr Xenia Uttridge industryThe disclosure requirements exceed those of comparable bodiesNoted, no amendment
DRAFT-TOOLS-DISCLA/006Dr Ndidi Ravensworth-Ilunga industryThe document should not describe uses outside the approved indicationNot accepted
DRAFT-TOOLS-DISCLA/003Nkechi Larsson-EkwuemeThe document is unreadable without specialist trainingAccepted in part
DRAFT-TOOLS-DISCLA/018Dr Georgiana MountstephenWhat the site collects about a reader is not stated in terms a reader can checkAccepted
DRAFT-TOOLS-DISCLA/004Vittoria QuintanilhaRecusal should follow automatically from any declared financial interestNot accepted
DRAFT-TOOLS-DISCLA/005Leonhard AchterbergDeclared interests should appear on the document rather than on a separate pageNoted, no amendment
DRAFT-TOOLS-DISCLA/011Dr Nadezhda LavrentievA superseded version should remain reachable from the version that replaced itNoted, no amendment
DRAFT-TOOLS-DISCLA/017Dr Jolanta UttridgeAbsence of evidence is presented in a form a reader will take as negative evidenceAccepted
18 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted7The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part3Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment5The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted3The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. An industry submission should be identifiable without reading the declared interest — arising from DRAFT-TOOLS-DISCLA/016. A submission made on behalf of a company is now identified as an industry submission on its face, at the head of the submission and in the disposition table, in addition to the declared interest published in full beneath it.
  2. The same concept is given three different names in one document — arising from DRAFT-TOOLS-DISCLA/009. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.
  3. The position of a contributor who withdraws consent is not stated — arising from DRAFT-TOOLS-DISCLA/013. The policy now states that a contributor may withdraw from the register at any time and that the register entry is removed, while a signed submission already published remains published, because the consultation record is a record of what was said and by…
  4. Whether external reviewers are paid is not stated — arising from DRAFT-TOOLS-DISCLA/014. The policy now states whether external review is remunerated, records any payment made in respect of a document in that document's front matter, and treats a payment received from the Institute as a declarable interest in the same way as any other.
  5. A party criticised in an assessment should have a right of reply — arising from DRAFT-TOOLS-DISCLA/001. A standing correction route is now published, corrections of fact are assessed and applied at any time with the change recorded in the amendment log, and a submission of substance received outside a window is held and published in the next comment period on…
  6. The terms on which the documents may be reused are not stated — arising from DRAFT-TOOLS-DISCLA/007. The reuse terms are now stated explicitly on the legal page and in the document footer, permitting quotation and reproduction with attribution and the document version, and requiring that any reproduction carry the certainty rating that accompanied the quoted…
  7. The secretariat answers submissions and is not itself named — arising from DRAFT-TOOLS-DISCLA/002. Every comment period now names the secretariat members responsible for it, with their declared interests, in the consultation front matter, so that the responses can be read against the interests of the people who wrote them.
  8. The document is unreadable without specialist training — arising from DRAFT-TOOLS-DISCLA/003. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
  9. What the site collects about a reader is not stated in terms a reader can check — arising from DRAFT-TOOLS-DISCLA/018. The statement now enumerates what is collected and what is not, and is written so that a reader can verify it from the page source, which is the only form of the statement that can be checked without trusting the Institute.
  10. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-TOOLS-DISCLA/017. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.